Alirocumab and evolocumab are monoclonal antibodies that target hepatic proprotein convertase subtilisin/kexin type 9 (PCSK9), decrease the circulating levels of atherogenic low-density lipoprotein cholesterol (LDL-C), alleviate endothelial inflammation and atherogenesis, and slow the progression of CKD 84. This evidence concerns the gene PCSK9 and chronic kidney disease.